54 results
6-K
EX-99.1
BLU
Bellus Health Inc
29 Mar 23
Current report (foreign)
5:26pm
2a RELIEF trial, and seeks compensatory damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other … as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16, 2021, Plaintiff stipulated to dismissal of all claims
6-K
EX-99.2
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
RELIEF trial, and seeks compensatory damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other reasonable
6-K
EX-99.1
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
damages, pre-judgment and post-judgment interest, as well as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16
6-K
EX-99.1
BLU
Bellus Health Inc
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
) CHEST 153 (1): 196 - 209. 2. Kuzniar et al. (2007) Mayo Clin. Proc. 82(1) 56 - 60. 3. Ryan NM, (2018) Expert Opin Pharmacother 19(7): 687 - 711. 4
6-K
EX-99.1
BLU
Bellus Health Inc
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
interest, as well as attorneys’ fees, expert fees, and any other reasonable costs and expenses. On November 16, 2021, Plaintiff stipulated to dismissal
6-K
EX-99.2
1vz76ao 03dgiha5w
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
6-K
EX-99.2
yy6ep8fmnc0
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
hd95ek
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
vccj n69en411qr
5 Apr 22
Current report (foreign)
4:07pm
40-F
EX-99.2
vnf bxq5tm3l
23 Feb 22
Annual report (Canada)
5:20pm
40-F
dz149
23 Feb 22
Annual report (Canada)
5:20pm
40-F
EX-99.3
n9tgpqn
23 Feb 22
Annual report (Canada)
5:20pm
40-F
EX-99.1
evnifj
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.2
5du81w 2td82og0xvh
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.1
hlphkg a3xuw4
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.2
7mg7f1
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.2
k2bw7837nxz3p6l64n
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
6-K
EX-99.1
x1hf4
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm
6-K
EX-99.1
v7ly2jcs n63ymyq
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm
6-K
EX-99.2
w2j963naae9b 1e94q
10 May 21
Condensed Consolidated Interim Financial Statements of
4:48pm